ModernMedicine Resource Center More Topics


Combination therapy seems best for relief of psoriasis

Combination therapy seems best for relief of psoriasis. Learn about which therapies work in the best combinations for your psoriasis patients.

Treatments for Plaque Psoriasis

Psoriasis from the patient's perspective
Psoriasis from the patient's perspectiveA patient with psoriasis asks dermatologists to put themselves in their patients' shoes and look at the condition from that perspective.
Psoriasis stress response in vitro
Psoriasis stress response in vitroRichard D. Granstein, M.D., chairman of dermatology, Weill Cornell Medical College, New York, has conducted research on how the nervous system and, perhaps, stress can make psoriasis worse or control the phenotypic expression of psoriasis.
Psoriasis and comorbidities a worldwide issueThe psychiatric comorbidities associated with psoriasis deserve more attention from physicians around the globe, experts say.
Psoriasis impact goes more than skin deepMany doctors, including dermatologists, would rather not address patients’ feelings about psoriasis. It’s part of how dermatologists protect themselves from bearing the burdens of patients’ woes, according to Richard Fried, M.D., Ph.D., a dermatologist and clinical psychologist in Yardley, Pennsylvania.
Psoriasis in patients with skin of colorPsoriasis in nonwhite patient populations is not well described, according to Andrew F. Alexis, M.D., M.P.H., director of the Skin of Color Center, at St. Luke’s Roosevelt Hospital, Mount Sinai Health System, New York.
Study reveals more side effects of methotrexate
Study reveals more side effects of methotrexateCommon gastrointestinal side effects to methotrexate may include anticipatory, associative and behavioral symptoms, aside from post-treatment nausea and vomiting, according to a new report.
Secukinumab shows superiority to etanercept
Secukinumab shows superiority to etanerceptRecent head-to-head clinical trial results with secukinumab (Novartis) and etanercept (Enbrel, Amgen) show a significant superiority of secukinumab in the treatment and management of patients with moderate-to-severe plaque psoriasis, perhaps heralding a new standard of care for this patient population.
Sustainability of ustekinumab established in patients with psoriatic arthritis
Sustainability of ustekinumab established in patients with psoriatic arthritisThe human interleukin-12 and interleukin-23 (IL-12/IL-23) inhibitor ustekinumab (Stelara, Janssen) is effective and is well tolerated in patients who have active psoriatic arthritis.
Many with psoriasis go untreated
Many with psoriasis go untreatedUp to 30 percent of patients with psoriasis do not seek medical care for their skin condition, patient surveys show.
Low rate of adverse events with adalimumab in long term
Low rate of adverse events with adalimumab in long termThe rate of adverse events in patients using adalimumab remains low over time, with infections indicated as the most common adverse event, according to a study.